Intra-Cellular Therapies (NASDAQ:ITCI) Earns Overweight Rating from Cantor Fitzgerald
Cantor Fitzgerald reaffirmed their overweight rating on shares of Intra-Cellular Therapies (NASDAQ:ITCI – Free Report) in a research report report published on Monday morning, Benzinga reports. They currently have a $130.00 target price on the biopharmaceutical company’s stock. Several other research analysts also recently issued reports on the stock. Canaccord Genuity Group boosted their price […]
More Stories
UN chief strongly condemns Mali terrorist attack
UN Secretary-General António Guterres has called for accountability following a “despicable” terrorist attack in Mali this week, his Spokesperson said...
Whole generation of children ‘lost’ amid ongoing Gaza war, UNICEF warns
Last October’s terror attacks by Hamas and other Palestinian armed groups on Israeli communities marked a devastating day for children,...
Security Council: Middle East envoy warns against escalation, highlights continued Israeli settlement activity
The UN envoy supporting peace efforts between Israelis and Palestinians voiced grave concern over the growing risk of widescale regional...
Blackstone Inc. (NYSE:BX) Receives Consensus Recommendation of “Hold” from Analysts
Shares of Blackstone Inc. (NYSE:BX – Get Free Report) have been given an average recommendation of “Hold” by the nineteen...
Reserve Bank Urged to Adapt After US Fed’s Aggressive Interest Rate Reduction
By Naziya Alvi Rahman The U.S. Federal Reserve announced on Sept. 18 that it would cut interest rates by half...
Coterra Energy Inc. (NYSE:CTRA) Short Interest Update
Coterra Energy Inc. (NYSE:CTRA – Get Free Report) was the target of a significant decrease in short interest in the...